Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 552.57M | 532.41M | 452.87M | 405.36M | 538.20M | 582.77M |
Gross Profit | 513.55M | 530.62M | 451.10M | 403.71M | 536.21M | 578.69M |
EBITDA | 68.23M | 46.81M | -9.16M | -42.37M | -105.18M | 66.27M |
Net Income | 28.99M | 10.06M | -28.21M | -88.72M | -104.38M | 45.45M |
Balance Sheet | ||||||
Total Assets | 1.14B | 1.16B | 1.11B | 1.11B | 1.15B | 1.04B |
Cash, Cash Equivalents and Short-Term Investments | 155.59M | 82.24M | 121.65M | 144.40M | 123.23M | 93.38M |
Total Debt | 95.34M | 96.92M | 103.16M | 106.80M | 41.37M | 46.56M |
Total Liabilities | 207.55M | 567.00M | 209.26M | 198.37M | 167.18M | 202.46M |
Stockholders Equity | 581.62M | 588.43M | 904.08M | 914.24M | 982.11M | 837.56M |
Cash Flow | ||||||
Free Cash Flow | -22.37M | -31.22M | -17.47M | -42.38M | -183.48M | -131.62M |
Operating Cash Flow | -12.01M | -18.37M | -6.69M | -26.87M | -162.62M | -107.86M |
Investing Cash Flow | -32.66M | -48.42M | -15.89M | 25.86M | -12.63M | -73.28M |
Financing Cash Flow | -9.11M | -9.67M | -6.22M | 63.84M | 213.24M | 201.25M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
61 Neutral | C$14.74B | 6.39 | 22.27% | 5.55% | 29.68% | -22.81% | |
60 Neutral | $417.99M | ― | 0.82% | ― | 20.41% | 93.09% | |
57 Neutral | $125.55M | ― | 3.19% | ― | 17.04% | 74.07% | |
51 Neutral | $5.27M | ― | -238.61% | ― | 2.40% | 94.65% | |
51 Neutral | $22.90M | 11.44 | -3.92% | ― | 0.48% | -127.19% | |
46 Neutral | $66.80M | ― | 0.80% | ― | 13.18% | 97.01% | |
45 Neutral | $12.26M | ― | -12.03% | ― | 158.74% | 14.86% |
On June 18, 2025, eHealth, Inc. announced that its CEO, Fran Soistman, will continue to serve until a successor is appointed, with a transition period extending to December 31, 2025. To ensure leadership stability during this period, Soistman will receive a retention cash award and a performance-based bonus, contingent on his continued service. Additionally, at the 2025 Annual Meeting of Stockholders, eHealth’s shareholders approved an amendment to the 2024 Equity Incentive Plan, increasing the maximum number of shares by 1,500,000, and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2025.
The most recent analyst rating on (EHTH) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Ehealth stock, see the EHTH Stock Forecast page.